Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis transfers products and cuts jobs in India; US call to build Alzheimer’s infrastructure; and Indian legal row over COVID spray product.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 18 February 2022, including: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis AG transfers products and cuts jobs in India; US call to build Alzheimer’s infrastructure; and Indian legal row over COVID spray product.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Lynparza On Track For Broad Frontline Use In Prostate Cancer" - Scrip, 15 Feb, 2022.)
(Also see "Sage/Biogen Depression Data Likely To Prolong Commercial Debate" - Scrip, 16 Feb, 2022.)
(Also see "Novartis-Dr Reddy’s Sales Pact, Job Cuts: Are Foreign Firms Altering India Push?" - Scrip, 14 Feb, 2022.)
(Also see "Work Now To Build The Alzheimer's Commercial Landscape, McClellan Advises" - Scrip, 15 Feb, 2022.)
(Also see "SaNOtize, Lupin In Legal Row Concerning COVID-19 Nasal Spray" - Scrip, 14 Feb, 2022.)